© Copyright 2025, All Rights Reserved
Company | Market Capitalization | Latest Funding Round | Key Innovations | Regulatory Approvals | Partnerships and Collaborations | Employee Count | Revenue Growth Rate | Awards and Recognitions | Market Focus Areas |
|---|---|---|---|---|---|---|---|---|---|
Elicio Therapeutics | 89.02M sources: 1 2 3 | Elicio Therapeutics recently secured $10 million in a registered direct offering. This funding round was announced approximately two months ago. The company is focused on developing cancer immunotherapies and aims to extend its operations through Q4 2025. sources: 1 2 3 | Elicio Therapeutics has developed several key innovations in the biotech sector, particularly in cancer immunotherapy. Their main products and innovations include:
AMP Platform: This platform utilizes advanced biomaterials technology combined with immunotherapeutic principles to create next-generat sources: 1 2 3 4 5 | Elicio Therapeutics has reached alignment with the FDA regarding its ELI-002 product, indicating that they expect to file a Biologics License Application (BLA) if supported by a planned Phase 3 trial. This suggests that they are in the process of obtaining regulatory approval for ELI-002. Additional sources: 1 2 | Elicio Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:
A clinical supply agreement with Regeneron to evaluate the safety and efficacy of ELI-002 in combination with Libtayo (cemiplimab) for KRAS-driven tumors.
A collaboration with sources: 1 2 3 | 32 sources: 1 2 3 4 5 | – | – | Elicio Therapeutics primarily focuses on developing cancer immunotherapies aimed at solid tumors, with a particular emphasis on challenging cancers such as pancreatic ductal adenocarcinoma (PDAC). sources: 1 |
Candel Therapeutics | 263.10M sources: 1 2 3 | Candel Therapeutics recently announced a public offering to raise $80 million. This funding round was launched to advance the development of their prostate cancer treatment pipeline. The offering consisted of 10,000,001 shares of common stock priced at $6.00 per share. The announcement was made appr sources: 1 2 3 | Candel Therapeutics has developed several key innovations and products in the biotech sector, primarily focusing on viral immunotherapies. Notable products include:
CAN-3110: A replication-competent herpes simplex virus (HSV) engineered to selectively kill cancer cells while sparing healthy cells. sources: 1 2 3 4 5 | Candel Therapeutics has received several regulatory designations for its products, including Orphan Drug Designation from the FDA for its lead product, CAN-2409, which is being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). Additionally, the company is preparing to submit a sources: 1 2 3 | Candel Therapeutics has established several significant partnerships in the biotech industry, including:
IDEA Pharma: A strategic partnership to advance the commercialization of its lead cancer immunotherapy, CAN-2409. This collaboration aims to enhance Candel's commercial strategy and support rela sources: 1 2 3 4 5 6 | 42 sources: 1 2 3 | – | Candel Therapeutics has received several awards and recognitions in the biotech field, including the prestigious Innovation Prize presented by Frost & Sullivan in 2012. This award acknowledges the company's capability to develop innovative treatments for challenging diseases, such as autoimmune diso sources: 1 2 | Candel Therapeutics primarily focuses on developing viral immunotherapies targeting various types of cancer. Their lead product candidate, CAN-2409, is currently in clinical trials for prostate cancer, non-small cell lung cancer (NSCLC), and borderline resectable pancreatic cancer (PDAC). The compan sources: 1 2 3 4 5 |
Gilead Sciences | $139.34 billion sources: 1 2 3 | Gilead Sciences recently announced a funding initiative that includes a total of $12.6 million in grant funding to 19 organizations aimed at improving HIV prevention, anti-stigma, and health equity efforts for Black cisgender and transgender women and girls in the United States. This funding was par sources: 1 2 | Gilead Sciences has developed several key innovations and products in the biotech sector, particularly in the field of antiviral drugs. Notable products include:
Sovaldi (sofosbuvir) - Approved in 2013 as a treatment for hepatitis C, recognized for its effectiveness.
Harvoni (ledipasvir/sofosbuvir) sources: 1 2 3 | Gilead Sciences has received several regulatory approvals for its products and technologies, including:
Lenacapavir: The U.S. FDA accepted Gilead's New Drug Application for Lenacapavir, a twice-yearly injectable for HIV prevention, under priority review. The European Medicines Agency (EMA) has also sources: 1 2 3 4 | Gilead Sciences has established several significant partnerships and collaborations in the biotech industry, including:
Genesis Therapeutics: Gilead entered a strategic collaboration with Genesis Therapeutics to discover and develop novel small molecule therapies using AI-driven drug discovery plat sources: 1 2 3 4 5 6 7 8 9 10 | 18,000 sources: 1 2 3 | -1% sources: 1 2 | Gilead Sciences has received several awards and recognitions in the biotech field, including: 1. 2021 Facility of the Year Awards - Special Recognition Award for Operational Agility due to COVID-19 impact. 2. Best Diversity, Equity & Inclusion (DE&I) Prize at Corporate Secretary and IR Magazine's ES sources: 1 2 3 4 5 6 | Gilead Sciences primarily focuses on the following therapeutic areas: virology, oncology, and inflammation. They are involved in the development of innovative medicines targeting diseases such as HIV, hepatitis, and various cancers. sources: 1 2 3 |
BioNTech | 21.85B sources: 1 2 3 | BioNTech has secured up to $145 million in funding from a global coalition against infectious diseases to help build mRNA vaccine plants in Africa. This funding was announced on May 29, 2024. sources: 1 | BioNTech has developed several key innovations and products in the biotech sector, particularly in immunotherapy and vaccines. Notably, they are recognized for the Pfizer-BioNTech COVID-19 vaccine, known as Comirnaty, which was the first approved mRNA-based vaccine. Additionally, BioNTech is advanci sources: 1 2 | BioNTech has received several regulatory approvals for its products and technologies, primarily related to its mRNA-based COVID-19 vaccines. Key approvals include:
BNT162b2 (Comirnaty): This was the first mRNA vaccine to receive emergency use authorization from the U.S. FDA in December 2020 and has sources: 1 2 3 4 5 | BioNTech has established several significant partnerships and collaborations in the biotech industry, including:
Tempus AI: A multi-year partnership focused on oncology data collaboration to enhance precision medicine.
Source
MediLink Therapeutics: BioNTech expanded its global strategic partner sources: 1 2 3 4 5 | 6300 sources: 1 2 3 | -78% sources: 1 2 | BioNTech has received several awards and recognitions in the biotech field, including:
The German Sustainability Award.
The Mustafa Prize.
The German Cancer Award.
In 2024, BioNTech was awarded "Prime" status by ISS ESG, placing it in the top 10% of all rated companies.
The Pfizer-BioNTech COVID-19 sources: 1 2 3 | BioNTech is primarily focused on the following therapeutic areas: 1. Oncology - Developing innovative cancer therapies. 2. Infectious Diseases - Including vaccines for COVID-19, malaria, and tuberculosis. 3. Autoimmune Diseases - Exploring treatments for various autoimmune conditions. 4. Regenerativ sources: 1 2 3 |
BioMarin Pharmaceutical | $13.03 billion sources: 1 2 3 4 5 | – | BioMarin Pharmaceutical has developed several key innovations and products in the biotech sector, particularly focused on rare diseases. Notable products include:
Aldurazyme® (laronidase) - A treatment for Mucopolysaccharidosis I (MPS I).
Brineura® (cerliponase alfa) - Used for treating CLN2 diseas sources: 1 2 | BioMarin Pharmaceutical has received several regulatory approvals for its products, including:
BRINEURA (cerliponase alfa) - Approved by the FDA as the first treatment for children with CLN2 disease.
VOXZOGO (vosoritide) - Approved by the FDA for increasing linear growth in children with achondropl sources: 1 2 3 4 5 | BioMarin Pharmaceutical has established several significant partnerships and collaborations in the biotech industry, including:
Howard University College of Pharmacy: BioMarin partnered with Howard University to develop a two-year fellowship in regulatory affairs aimed at early-career professionals sources: 1 2 3 4 5 | 3,401 sources: 1 2 3 | 15.42% sources: 1 2 3 | BioMarin Pharmaceutical has received several awards and recognitions in the biotech field, including:
2023 Pantheon Awards - BioMarin was recognized for its innovative achievements in biotechnology alongside Twist Bioscience.
Company of the Year - BioMarin was honored as Company of the Year in the B sources: 1 2 3 4 5 6 | BioMarin Pharmaceutical primarily focuses on developing treatments for serious diseases and medical conditions, particularly in the following therapeutic areas:
Central Nervous System - Targeting conditions affecting the brain and spinal cord.
Cardiovascular - Addressing heart-related diseases.
Musc sources: 1 2 |
Ultragenyx Pharmaceuticals | $3.32 billion sources: 1 2 3 | Ultragenyx Pharmaceuticals is looking to raise approximately $350 million in a public stock offering, which was announced on June 14, 2024. The offering was priced at around $39 per share. sources: 1 | Ultragenyx Pharmaceuticals has developed several key innovations and products in the biotech sector, particularly focused on rare and ultrarare genetic diseases. Notable products include:
Burosumab (Crysvita) - Approved for the treatment of X-linked hypophosphatemia (XLH).
Triheptanoin (UX007) - Ap sources: 1 2 3 | Ultragenyx Pharmaceuticals has received several regulatory approvals for its products, including:
Burosumab (Crysvita) - Approved by the FDA for the treatment of X-linked hypophosphatemia (XLH).
Triheptanoin (Dojolvi) - Approved by the FDA for the treatment of long-chain fatty acid oxidation disorde sources: 1 2 3 4 5 | Ultragenyx Pharmaceuticals has established several significant partnerships and collaborations in the biotech industry, including:
Solid Biosciences: A strategic collaboration to develop and commercialize new gene therapies for Duchenne muscular dystrophy, announced on October 23, 2020.
Mereo BioPha sources: 1 2 3 4 5 6 | 1276 sources: 1 2 3 4 5 | 19% sources: 1 2 | Ultragenyx Pharmaceuticals has received several awards and recognitions in the biotech field, including:
Emil Kakkis, M.D., Ph.D., the CEO of Ultragenyx, received the 2021 Pantheon Leadership Award from California Life Sciences, which also recognized Ultragenyx as a finalist for Company of the Year. sources: 1 2 3 4 5 | Ultragenyx Pharmaceuticals primarily focuses on developing therapies for rare and ultrarare genetic diseases. Their therapeutic areas include metabolic genetic diseases, neurological genetic disorders, and rare pediatric conditions. Specific conditions they are targeting include Glycogen Storage Dis sources: 1 2 |
BeiGene | 31.17B sources: 1 2 3 4 | – | BeiGene has developed several key innovations and products in the biotech sector, particularly in cancer treatment. Notable products include:
Tislelizumab (Tevimbra): A PD-1 inhibitor used for treating various cancers, including esophageal squamous cell carcinoma (ESCC) and gastric cancer. It has g sources: 1 2 3 4 | BeiGene has received several regulatory approvals for its products, including:
TEVIMBRA (tislelizumab): Approved by the U.S. FDA for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. It also received a positive opinion from the European Medicines Ag sources: 1 2 3 4 | BeiGene has established several significant partnerships and collaborations in the biotech industry, including:
ImmunityBio: A collaboration and supply agreement was signed to work together on research initiatives.
Source
MAIA Biotechnology: A clinical supply agreement to evaluate the drug THIO sources: 1 2 3 4 5 | 10,600 sources: 1 2 3 4 | 74% sources: 1 2 | BeiGene has received several awards and recognitions in the biotech field, including: 1. Manufacturer of the Year by the National Association of Specialty Pharmacy (NASP) in October 2024, recognizing its innovation and leadership in the specialty pharmacy sector. 2. 2023 PM360 Silver Pharma Choice A sources: 1 2 3 4 | BeiGene primarily focuses on two therapeutic areas: Hematology and Solid Tumors. They are committed to developing innovative therapies for these specific types of cancer, addressing significant unmet medical needs in these fields. sources: 1 2 3 |
AstraZeneca | $224.51 billion sources: 1 2 3 4 5 6 7 | AstraZeneca recently announced a funding round involving a C$820 million (approximately US$570 million) investment in Canada. This investment aims to advance their global hub and clinical delivery, creating around 700 new scientific and high-skilled jobs in the Greater Toronto Area. The announcement sources: 1 2 | AstraZeneca has developed several key innovations and products in the biotech sector, including:
Biologics: First or best-in-class antibody, peptide, and protein therapeutics targeting high unmet medical needs, especially in oncology and immune-related disorders.
Antibody Drug Conjugates: These com sources: 1 2 | AstraZeneca has received several regulatory approvals for its products and technologies, including:
Calquence (acalabrutinib) - Expanded FDA approval for the first-line treatment of mantle cell lymphoma.
Wainua (eplontersen) - Granted first-ever regulatory approval in the US for the treatment of ad sources: 1 2 3 | AstraZeneca has established several significant partnerships and collaborations in the biotech industry, including:
Collaboration with Immunai: AstraZeneca partnered with Immunai, an AI and biotech firm, in a collaboration worth $18 million aimed at transforming cancer drug development and optimizi sources: 1 2 3 4 5 | 89,900 sources: 1 2 3 | 3% sources: 1 2 | AstraZeneca has received several awards and recognitions in the biotech field, including:
The AstraZeneca Award from the Biochemical Society, which recognizes outstanding work leading to biomedical advances.
Two awards within the Research and Development category at the Clinical Trials Arena Excelle sources: 1 2 3 4 5 | AstraZeneca primarily focuses on the following therapeutic areas: oncology, cardiovascular, renal, metabolism, respiratory, and immunology. sources: 1 |
UroGen Pharma | 496.90M sources: 1 2 3 | UroGen Pharma announced a funding round on July 27, 2023, in which they raised approximately $120 million through a private placement of ordinary shares. This funding is intended to support their ongoing development and commercialization efforts. sources: 1 2 3 | UroGen Pharma has developed several key innovations and products in the biotech sector, particularly focused on urological cancers. Notable among these is the RTGel® reverse-thermal hydrogel, a proprietary sustained-release hydrogel-based platform technology designed to enhance the therapeutic profi sources: 1 2 3 | UroGen Pharma has received regulatory approvals for several products and technologies, including: 1. Jelmyto® (mitomycin) for pyelocalyceal solution - This is the first FDA-approved treatment utilizing UroGen's novel RTGel® technology, which is designed for the treatment of patients with low-grade, sources: 1 2 3 4 | UroGen Pharma has established several significant partnerships and collaborations in the biotech industry, including:
MD Anderson Cancer Center: UroGen Pharma announced a strategic research collaboration with MD Anderson to advance investigational treatments for high-grade bladder cancer. This coll sources: 1 2 3 4 5 | 201 sources: 1 2 | – | – | UroGen Pharma primarily focuses on uro-oncology, specifically targeting treatments for urological cancers. The company is dedicated to developing innovative therapies that enhance treatment options for patients living with these conditions, utilizing breakthrough technology to create transformative sources: 1 2 3 4 |
Amgen | $164.25 billion sources: 1 2 3 | Amgen borrowed $4 billion under a Term Loan Credit Agreement on October 6, 2023. This funding is part of a financial strategy related to the acquisition of Horizon Therapeutics, rather than a traditional funding round. sources: 1 | Amgen has developed several key innovations and products in the biotech sector, including:
Enbrel (etanercept) - A biologic drug used to treat autoimmune diseases such as rheumatoid arthritis.
Prolia (denosumab) - Used for the treatment of osteoporosis in postmenopausal women.
Xgeva (denosumab) - A sources: 1 2 3 | Amgen has received several regulatory approvals for its products and technologies, including: 1. LUMAKRAS (sotorasib) - The first KRASG12C inhibitor to receive regulatory approval in the U.S. under accelerated approval in May 2021. It has been approved for use in treating certain types of cancer. 2. sources: 1 2 3 4 | Amgen has established several significant partnerships and collaborations in the biotech industry, including:
MediLink Therapeutics: A global clinical trial collaboration and supply agreement was announced to advance clinical trials.
Source
Merck: Amgen and Merck became the first industry partn sources: 1 2 3 4 5 6 | 26,700 sources: 1 2 3 4 | 7% sources: 1 2 | Amgen has received several awards and recognitions in the biotech field, including:
Ranked #6 on Fortune's list of the World's Most Admired Companies within the biopharmaceutical peer group.
The Amgen Biotech Experience was shortlisted for the Corporate Social Responsibility Programme of the Year at sources: 1 2 3 | Amgen primarily focuses on four therapeutic areas: general medicine, rare disease, inflammation, and oncology. They aim to deliver innovative medicines that help people live longer, fuller, and happier lives. sources: 1 2 3 |
AbbVie | $362.98 billion sources: 1 2 3 | AbbVie recently engaged in a funding round related to a partnership with EvolveImmune, which started at $65 million. This information was reported approximately five months ago. Additionally, the AbbVie Foundation made a $75 million donation to the University of Chicago Medicine for a new cancer cen sources: 1 2 | AbbVie has developed several key innovations and products in the biotech sector, including:
Humira (adalimumab) - Once the world's top-selling drug, Humira is used to treat various autoimmune diseases.
Imbruvica (ibrutinib) - A treatment for certain types of blood cancers, particularly chronic lymp sources: 1 2 3 4 5 | AbbVie has received several regulatory approvals for its products and technologies, including:
VYALEV™ (foscarbidopa and foslevodopa) - Approved by the FDA on October 17, 2024, as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults living with advanced Parkinson's sources: 1 2 3 | AbbVie has established several significant partnerships and collaborations in the biotech industry, including:
Xilio Therapeutics: AbbVie signed a collaboration and option agreement to develop novel tumor-activated immunotherapies, with an upfront payment of $52 million.
Source
EvolveImmune The sources: 1 2 3 4 5 6 | 50,000 sources: 1 2 3 4 | -6.44% sources: 1 2 3 | AbbVie has received several awards and recognitions in the biotech field, including being named "Biopharma Company of the Year" at the 2021 Irish Pharma Industry Awards. Additionally, AbbVie won the "Sustainability Initiative of the Year" at the same event and was a runner-up for the overall "Pharma sources: 1 2 3 4 5 | AbbVie primarily focuses on several therapeutic areas, including Immunology, Oncology, Neuroscience, Eye Care, and Aesthetics. Additionally, they have interests in other specialty areas such as virology and chronic progressive diseases. sources: 1 2 3 |
Pivot Bio | $2 billion sources: 1 2 3 | Pivot Bio recently closed a $430 million Series D funding round on August 29, 2023. The funding was led by DCVC and Temasek, among other investors. sources: 1 2 | Pivot Bio has developed several key innovations and products in the biotech sector, primarily focused on microbial nitrogen solutions for agriculture. Notable products include:
PROVEN G3: This is the third generation of their nitrogen solution for corn, which incorporates powerful new modes of acti sources: 1 2 3 | Pivot Bio's products have received regulatory approvals from the USDA, FDA, and EPA in the United States. They are approved for distribution and use in 47 U.S. states, excluding Alaska, California, and Hawaii. The company emphasizes that their products are regulated in every country where they opera sources: 1 2 3 | Pivot Bio has established several significant partnerships in the biotech industry, including:
A distribution partnership with MFA Incorporated, announced in January 2025, aimed at enhancing the availability of their innovative agricultural solutions.
A strategic distribution partnership with Hefty sources: 1 2 3 4 | 371-550 sources: 1 2 3 | 60% sources: 1 2 | Pivot Bio has received several awards and recognitions in the biotech field, including:
Recognition as one of the "World's 50 Most Innovative Companies" by Fast Company.
Named to TIME's list of the "Best Inventions" for their N-OVATOR® program in 2024.
Included in the FoodTech 500 and THRIVE TOP50 A sources: 1 2 3 4 5 | Pivot Bio primarily focuses on the agricultural market, specifically targeting crop production through innovative microbial nitrogen solutions. Their products are designed to optimize nitrogen delivery directly to plant roots, thereby enhancing crop yields and sustainability. They aim to transform a sources: 1 2 3 |
Vertex Pharmaceuticals | $124.90 billion sources: 1 2 3 4 | Vertex Pharmaceuticals completed a Post-IPO Secondary funding round on July 10, 2024, raising approximately $1,111,135. sources: 1 2 | Vertex Pharmaceuticals has developed several key innovations and products in the biotech sector, particularly focused on cystic fibrosis (CF) and other serious diseases. Some of their notable products include:
KAFTRIO® (elexacaftor/tezacaftor/ivacaftor) - A combination therapy for cystic fibrosis t sources: 1 2 3 4 | Vertex Pharmaceuticals has received several regulatory approvals for its products and technologies, including:
CASGEVY™ (exagamglogene autotemcel) - Approved by the U.S. FDA for the treatment of sickle cell disease in December 2023. This approval marks the first regulatory authorization of a CRISPR sources: 1 2 3 4 | Vertex Pharmaceuticals has established several significant partnerships and collaborations in the biotech industry, including:
Collaboration with Orna Therapeutics: Vertex partnered with Orna Therapeutics in a $4 billion collaboration to develop next-generation gene therapies for sickle cell diseas sources: 1 2 3 4 5 6 7 8 | 5400 sources: 1 2 3 | 10.51% sources: 1 2 | Vertex Pharmaceuticals has received several notable awards and recognitions in the biotech field, including:
The 2024 Breakthrough Prize in Life Sciences awarded to three of its researchers for developing life-transforming drug combinations.
Recognition from MassBio, where Vertex Pharmaceuticals was sources: 1 2 3 4 | Vertex Pharmaceuticals primarily focuses on therapeutic areas including cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. They are also involved in research and development for other serious diseases, such as type 1 diabetes and various kidney diseases. sources: 1 2 3 |
Arrowhead Pharmaceuticals | $1.74 billion sources: 1 2 3 | Arrowhead Pharmaceuticals announced a $500 million strategic senior secured credit facility on August 8, 2024. This facility includes $400 million funded at the close, with an additional $100 million available at Arrowhead's option. sources: 1 | Arrowhead Pharmaceuticals has developed several key innovations and products in the biotech sector, primarily focusing on RNA interference (RNAi) therapies. Notable products include:
Plozasiran (ARO-APOC3): Designed to reduce the production of Apolipoprotein-CIII (ApoC3) to lower triglyceride level sources: 1 2 3 | Arrowhead Pharmaceuticals has received several regulatory approvals and designations for its products, particularly for its investigational drug plozasiran. Key approvals include:
Acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for plozasiran, aimed at treat sources: 1 2 3 4 5 | Arrowhead Pharmaceuticals has established significant partnerships in the biotech industry, notably a global licensing and collaboration agreement with Sarepta Therapeutics. This agreement, announced in November 2024, involves Sarepta paying Arrowhead $500 million in cash, along with a $325 million sources: 1 2 3 | 525 sources: 1 2 3 | -1.03% sources: 1 2 | – | Arrowhead Pharmaceuticals is primarily focused on several therapeutic areas, including cardiometabolic diseases, pulmonary diseases, and inflammatory pulmonary diseases. Specific conditions they are targeting within these areas include severe hypertriglyceridemia, dyslipidemia, cardiovascular diseas sources: 1 2 3 |
REGENXBIO | 358.37M sources: 1 2 3 | REGENXBIO recently secured a strategic partnership with Nippon Shinyaku, which was announced in March 2025. This partnership includes an upfront payment of $110 million and potential milestone payments totaling up to $700 million, bringing the total value of the partnership to $810 million. sources: 1 2 | REGENXBIO has developed several key innovations and products in the biotech sector, particularly in gene therapy for serious health conditions. Notable products include:
ABBV-RGX-314: A gene therapy candidate for treating wet age-related macular degeneration (AMD) and diabetic retinopathy, utilizin sources: 1 2 3 4 5 | REGENXBIO has received several regulatory approvals and designations for its products and technologies, including:
RGX-121: A Biologics Licensing Application (BLA) has been submitted for RGX-121, which is on track for potential FDA approval in the second half of 2025. The company has also had a suc sources: 1 2 3 4 5 6 | REGENXBIO has established several significant partnerships in the biotech industry, including:
Nippon Shinyaku: REGENXBIO entered a strategic partnership with Nippon Shinyaku to develop and commercialize gene therapies RGX-121 and RGX-111 for MPS diseases. This partnership includes an upfront payme sources: 1 2 3 4 5 | 353 sources: 1 2 3 4 5 | 45.3% sources: 1 2 | REGENXBIO has received several recognitions in the biotech field, including being awarded the Washington Post's Top Workplaces in 2021, 2022, and 2023. Additionally, they received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for their RGX-121 gene therapy for Hunter syndrome. sources: 1 2 | REGENXBIO is primarily focused on developing gene therapy product candidates in the following therapeutic areas: retinal diseases, metabolic disorders, and neurodegenerative conditions. Their mission is to leverage the curative potential of gene therapy to improve lives. sources: 1 2 3 |
SpringWorks Therapeutics | 3.49B sources: 1 2 3 | The latest funding round for SpringWorks Therapeutics was a post-IPO round that took place on September 7, 2022, where the company raised $225 million. This round included participation from five investors, including EcoR1, Boxer Capital, Invus, Deerfield, and Perceptive Advisors. sources: 1 2 | SpringWorks Therapeutics has developed key innovations in the biotech sector, particularly in oncology. Notable products include:
Nirogacestat: A gamma secretase inhibitor being evaluated in combination therapies for multiple myeloma.
Mirdametinib: An FDA-approved treatment for adult and pediatric p sources: 1 2 3 | SpringWorks Therapeutics has received regulatory approvals for the following products:
GOMEKLI™ (mirdametinib) - Approved by the FDA for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (NF1-PN). This approval was based on positive sources: 1 2 3 4 | SpringWorks Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:
Rappta Therapeutics: In September 2023, SpringWorks entered into a global license agreement with Rappta Therapeutics for the development of a novel cancer treatment, RPT0 sources: 1 2 3 4 5 6 7 | 305 sources: 1 2 | 23% sources: 1 2 3 4 | SpringWorks Therapeutics received the 2021 Innovation in Medicine Award at the Children's Tumor Foundation National Gala. This award recognizes the company's contributions to innovative medicine, particularly in the field of rare cancers. sources: 1 2 | SpringWorks Therapeutics primarily focuses on developing innovative medicines for rare tumors, hematological cancers, and biomarker-defined metastatic solid tumors. Their therapeutic areas include treatments for desmoid tumors and neurofibromatosis type 1, utilizing a precision oncology approach to sources: 1 2 3 4 |
Invaio | – | – | Invaio Sciences has developed several key innovations and products in the biotech sector focused on sustainable agriculture. These include:
Biologicals by Design™ Platform: This platform utilizes advanced technologies such as generative AI and deep machine learning to create programmable peptides f sources: 1 2 3 | Invaio Sciences has received regulatory approval from the Florida Department of Agriculture and Consumer Services (FDACS) for its Trecise™ technology, which is designed to deliver ArborBiotic™ for the suppression of citrus greening in orange crops. This approval marks the first registration for comm sources: 1 2 3 | Invaio Sciences has established several significant partnerships and collaborations in the biotech industry, including:
Collaboration with Louis Dreyfus Company: In January 2024, Invaio announced a collaboration aimed at mitigating citrus greening disease while improving crop quality, yield, and l sources: 1 2 3 | 90 sources: 1 2 3 | – | Invaio Sciences has been recognized as one of "America's Top GreenTech Companies 2024." However, there are no specific awards or recognitions mentioned that are strictly categorized under the biotech field. sources: 1 | Invaio Sciences primarily focuses on crop health solutions, specifically targeting areas such as tree health, citrus health, vegetable health, and row crop health. Their innovative approach includes the development of biological crop protection solutions and precision delivery technologies aimed at sources: 1 2 3 4 5 6 |
Sanofi | $132.66 billion sources: 1 2 3 | Sanofi's latest funding round was for Agomab Therapeutics, which secured $89 million in Series D funding announced on October 25, 2024. This funding is aimed at supporting clinical trials for fibrotic disease treatments. Additionally, Sanofi-backed Abcuro raised $200 million in Series C funding on F sources: 1 2 | Sanofi has developed several key innovations and products in the biotech sector, particularly focusing on immunology and therapeutic platforms. Notable innovations include:
Dupixent (IL4xIL13 mAb) - A monoclonal antibody for multiple indications, including ulcerative colitis and chronic obstructive sources: 1 2 | Sanofi has received several regulatory approvals for its products and technologies, including:
Sarclisa (isatuximab) - Approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Dupixent (dupilumab) - Approved in over 6 sources: 1 2 3 4 5 | Sanofi has established several significant partnerships and collaborations in the biotech industry, including:
Collaboration with Healx: Sanofi partnered with Healx, a UK-based biotech specializing in rare diseases, to utilize artificial intelligence for identifying novel rare disease indications ( sources: 1 2 3 4 5 6 | 86,088 sources: 1 2 3 | 5.11% sources: 1 2 | Sanofi has received several awards and recognitions in the biotech field, including:
Sanofi iDEA-TECH Awards - Recognizes innovative research collaborations in North America.
Sanofi iAwards - Acknowledges outstanding contributions in scientific research.
Sanofi - Institut Pasteur Awards - Honors sci sources: 1 2 3 4 5 | Sanofi is primarily focused on several therapeutic areas, including immunology, neurology, oncology, rare diseases, rare blood disorders, cardiovascular diseases, and diabetes. These areas are part of their commitment to transforming scientific discoveries into healthcare solutions. sources: 1 2 3 |
Locus AG | – | – | Locus AG has developed several key innovations and products in the biotech sector, particularly focused on agricultural biologicals. These include:
Liquid Inoculants for Legumes: Microbial inoculants that enhance nitrogen fixation and improve yields in crops like soybeans and peanuts.
Bombigro for sources: 1 2 3 4 5 | Locus AG has received several regulatory approvals for its products, including the following notable ones:
Expanded Regulatory Approvals: Locus AG's unique probiotic for crops has received expanded regulatory approvals across various states, including Alabama and Arizona, as of August 9, 2018.
Organ sources: 1 2 | Locus AG has established several significant partnerships in the biotech industry, including:
A partnership with Nori announced on January 29, 2020, which provides a pathway for payments to farmers harvesting carbon.
Collaboration with EarthX to utilize Locus AG's soil "probiotics" for carbon di sources: 1 2 3 | 100+ sources: 1 2 3 | – | Locus AG has received several awards and recognitions in the biotech field, including:
NREL's Industry Growth Forum 2020 Outstanding Venture Award - Recognized for its soil probiotics and delivery system that boost agricultural yields and carbon sequestration.
Shortlisted for Best New Biological in sources: 1 2 3 4 5 6 | Locus AG primarily focuses on biological solutions for various agricultural sectors, including row crops, fruits and vegetables, vineyards and orchards, and turf and ornamentals. Their products are designed to enhance crop yields, improve soil quality, and increase nutrient uptake, which are critica sources: 1 |
Ionis Pharmaceuticals | 4.52B sources: 1 2 3 4 | Ionis Pharmaceuticals recently completed a public offering, pricing 11,500,000 shares of its common stock at $43.50 per share, raising a total of $500.3 million. This funding round was announced on September 10, 2024. sources: 1 2 | Ionis Pharmaceuticals has developed several key innovations and products in the biotech sector, particularly focusing on RNA-targeted therapies. The company has six marketed medicines, including:
Spinraza (Nusinersen) - a treatment for spinal muscular atrophy.
Tegsedi (Inotersen) - used for the trea sources: 1 2 3 | Ionis Pharmaceuticals has received several regulatory approvals for its products, including:
TRYNGOLZA™ (olezarsen) - Approved by the U.S. Food and Drug Administration (FDA) as the first-ever treatment for adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet, with the approval d sources: 1 2 3 4 5 | Ionis Pharmaceuticals has established several significant partnerships and collaborations in the biotech industry, including:
Collaboration with Novartis: Ionis entered a collaboration and license agreement with Novartis to advance a program targeting Lp(a) for cardiovascular disease, building on a sources: 1 2 3 4 5 6 | 927 sources: 1 2 3 4 | 34% sources: 1 2 | Ionis Pharmaceuticals has received several awards and recognitions in the biotech field, including:
The Prix Galien USA Award for the Best Biotechnology Product in 2020 for TEGSEDI, which is the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloi sources: 1 2 3 4 | Ionis Pharmaceuticals is primarily focused on therapeutic areas including neurology, cardiology, and select areas of high patient needs. They aim to provide new solutions for serious diseases, particularly in common intractable neurologic conditions and cardiometabolic disorders. sources: 1 2 3 |
Benson Hill | $1.52M sources: 1 2 3 | Benson Hill recently filed for Chapter 11 bankruptcy protection and is seeking $11 million in financing to maintain operations during the restructuring process. This indicates that there has not been a recent funding round in the traditional sense, as the company is currently focused on stabilizing sources: 1 2 3 4 | Benson Hill has developed several key innovations and products in the biotech sector, particularly focusing on advanced soybean varieties. Notable innovations include:
Ultra-High Protein Soybeans: These varieties are designed to enhance the nutritional value of animal feed.
Low Oligosaccharide Soybe sources: 1 2 | – | Benson Hill has established several significant partnerships and collaborations in the biotech industry, including:
ADM Partnership: Benson Hill entered a strategic partnership with Archer Daniels Midland (ADM) to scale ultra-high protein soy for North American food ingredient markets. This collabo sources: 1 2 3 4 5 6 7 8 9 | 270 sources: 1 2 | 24% sources: 1 2 3 | Benson Hill has received several awards and recognitions in the biotech field, including:
Overall FoodTech Company of the Year awarded by AgTech Breakthrough for two consecutive years, recognizing the company as a leading platform driving the plant-based revolution.
AI-based Solution of the Year at sources: 1 2 3 4 | Benson Hill primarily focuses on three market areas: better feed, better food, and better fuel. These areas aim to meet the demand for higher protein and energy-dense feed ingredients for animal producers, provide more nutritious and sustainable food alternatives for consumers, and develop renewable sources: 1 2 3 |
Corteva Agriscience | $33.77B sources: 1 2 | Corteva Agriscience's latest funding round was a grant round that took place on May 11, 2023, in which the company raised $1.2 billion. sources: 1 2 | Corteva Agriscience has developed several key innovations and products in the biotech sector, particularly in biological products aimed at enhancing agricultural productivity and sustainability. Their offerings include:
Biostimulants: Products like Utrisha® N, which enhance nitrogen efficiency, and sources: 1 2 3 | Corteva Agriscience has received various regulatory approvals for its crop protection products, which meet or exceed regulatory standards globally. The process for securing these approvals is extensive, typically taking an average of 11 years from discovery to commercialization. Corteva emphasizes t sources: 1 2 3 | Corteva Agriscience has established several significant partnerships and collaborations in the biotech industry, including:
Gates Agricultural Innovations: A collaboration announced in February 2025 to develop novel seed technologies aimed at enhancing sustainable crop productivity and climate resi sources: 1 2 3 4 5 6 | 22,500 sources: 1 2 3 4 5 | -1% sources: 1 2 | Corteva Agriscience has received several awards and recognitions in the biotech field, including:
The 2024 Iowa Biotech Leader Award, recognizing contributions to the biotech industry.
The Crop Science Award for "Best Industry Collaboration" in 2022, awarded for collaboration with BASF Agricultural sources: 1 2 3 4 | Corteva Agriscience primarily focuses on three core market areas: Seeds, Crop Protection, and Digital Agriculture. The Seeds segment includes a variety of crops such as corn, soybean, sunflower, canola, rice, and wheat. The Crop Protection segment offers herbicides, insecticides, fungicides, and bio sources: 1 2 |
Albatroz Therapeutics | – | Albatroz Therapeutics recently secured $3 million in funding to develop therapies targeting tissue remodeling, which is critical in stopping cancer growth and treating arthritis. This funding round was announced on April 25, 2023. sources: 1 2 3 | Albatroz Therapeutics is focused on developing first-in-class antibody therapeutics targeting a novel protein critical to the extracellular matrix, which is significant for treating solid tumors and inflammatory diseases such as arthritis. Their key innovations include:
Development of therapeutic an sources: 1 2 3 4 | – | Albatroz Therapeutics has established significant partnerships in the biotech industry, including: 1. Amgen and NSG BioLabs: Albatroz Therapeutics was announced as the winner of the first Amgen Golden Ticket in Singapore, which is aimed at boosting the capabilities of biotech startups in the region. sources: 1 2 3 | 10-25 sources: 1 2 3 | – | Albatroz Therapeutics received the first Golden Ticket prize from Amgen in Singapore, which recognized the viability of its science and business plan. This award includes a one-year free residency in NSG Biolabs' fully-equipped laboratory. sources: 1 2 3 4 | Albatroz Therapeutics is primarily focused on developing first-in-class antibodies targeting a novel mechanism critical to the integrity of the extracellular matrix. Their therapeutic areas of interest include cancer and inflammatory diseases. sources: 1 |
Allozymes | – | Allozymes, a Singapore-based biotechnology company, raised $15 million in a Series A funding round. This funding was announced on May 15, 2024, and was led by Seventure Partners and Xora Innovation. The company aims to utilize this investment to enhance its enzyme discovery and engineering capabilit sources: 1 2 | Allozymes has developed several key innovations and products in the biotech sector, including:
A proprietary ultra-high-throughput microfluidics platform that enables the rapid development and screening of enzymes, analyzing over 20 million variants per day.
Enzymes designed for efficient small mole sources: 1 2 3 4 | – | Allozymes has established several significant partnerships in the biotech industry, including:
Collaboration with Bonumose: Announced on March 31, 2025, this partnership aims to accelerate enzyme innovations for beneficial food and supplement ingredients. Source
Partnership with Adisseo: This stra sources: 1 2 3 4 5 | 35 sources: 1 2 | – | Allozymes has received several awards and recognitions in the biotech field, including:
The Future Food Asia Award, which they won in recognition of their innovative contributions to the food industry.
They were recognized for having the Most Innovative Service or Technology Supporting Food & Bevera sources: 1 2 3 | Allozymes is targeting several primary market focus areas, including:
Pharmaceuticals: Developing enzymes for more efficient small molecule development and production.
Life Sciences & Diagnostics: Creating next-generation enzymes for various applications.
Food & Nutrition: Upcycling food compa sources: 1 2 3 |
Hummingbird Bioscience | – | Hummingbird Bioscience was involved in a recent funding round through its licensing of technology to Callio Therapeutics, which secured $187 million in a Series A financing round that closed on March 3, 2023. This funding is aimed at advancing multi-payload antibody-drug conjugate technology. sources: 1 2 3 | Hummingbird Bioscience has developed several key innovations and products in the biotech sector, particularly focusing on monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). Notable products include:
HMBD-001: A monoclonal antibody targeting HER3, currently in clinical trials for squa sources: 1 2 3 | Hummingbird Bioscience has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a first-in-human phase 1 trial of its product HMBD-001, which is aimed at treating advanced cancers. sources: 1 2 | Hummingbird Bioscience has established several significant partnerships and collaborations in the biotech industry, including:
Synaffix: A $150 million licensing agreement to develop a next-generation antibody-drug conjugate (ADC).
Source
Novogene: A strategic partnership aimed at expanding pre sources: 1 2 3 4 5 6 | 86 sources: 1 2 3 | – | Hummingbird Bioscience has received several awards and recognitions in the biotech field, including:
The Most Promising Innovation title at Singapore's SG:D Techblazer Awards 2020, which is the nation's highest accolade for tech innovation.
The BioSpectrum Asia Startup of the Year Award 2022, with S sources: 1 2 | Hummingbird Bioscience primarily focuses on engineering biotherapeutics, particularly antibody-based therapeutics, targeting precision medicine for cancer and autoimmune diseases. sources: 1 |
Explore this dataset in full detail with Extruct AI.
Our platform makes it easy to analyze, filter, and export the data for your specific research needs.